News
TRDA
13.16
-2.95%
-0.40
Weekly Report: what happened at TRDA last week (0422-0426)?
Weekly Report · 6d ago
Entrada Therapeutics, Inc.: Report of proposed sale of securities
Press release · 04/26 16:25
Edgewise gets EU orphan drug status for muscular dystrophy drug
Edgewise gets EU orphan drug status for muscular dystrophy drug. Edgewise Therapeutics has received orphan drug designation from EU regulators for its drug candidate sevasemten. The drug candidate is in the treatment of Becker muscular dy Strophy and Duchenne muscular dystrophy.
Seeking Alpha · 04/23 14:29
Weekly Report: what happened at TRDA last week (0415-0419)?
Weekly Report · 04/22 11:12
Entrada Therapeutics, Inc.: Report of proposed sale of securities
Press release · 04/17 22:42
Weekly Report: what happened at TRDA last week (0408-0412)?
Weekly Report · 04/15 11:04
GLYC, APLD and AUTL are among after hour movers
Seeking Alpha · 04/11 21:00
12 Health Care Stocks Moving In Thursday's After-Market Session
Ontrak (NASDAQ:OTRK) shares increased by 18.7% to $0.45 during Thursday's after-market session. Ocuphire Pharma stock rose 7.82% and Lyell Immunopharma stock rose by 7.5%. Motus GI Hldgs stock declined by 32.6% during the after- market session.
Benzinga · 04/11 20:31
Insiders Buying America's Car-Mart And 2 Other Stocks
U.S. Stocks closed lower on Wednesday. There were a few notable insider trades. Insider purchases indicate confidence in the company's prospects or that they view the stock as a bargain. America's Car-Mart, Inc. And Entrada Therapeutics made recent notable insider purchases.
Benzinga · 04/11 10:41
Weekly Report: what happened at TRDA last week (0401-0405)?
Weekly Report · 04/08 11:09
Weekly Report: what happened at TRDA last week (0325-0329)?
Weekly Report · 04/01 11:07
Wednesday 3/27 Insider Buying Report: GO, TRDA
NASDAQ · 03/27 14:34
Weekly Report: what happened at TRDA last week (0318-0322)?
Weekly Report · 03/25 11:10
Around $5M Bet On This Communication Services Stock? Check Out These 4 Stocks Insiders Are Buying
U.S. Stocks closed higher on Thursday. There were a few notable insider trades. Cardlytics, Inc. And Entrada Therapeutics made notable purchases. Energy Services of America Corporation and Phunware also made notable insider purchases. An insider purchase indicates confidence in the company's prospects or a bargain.
Benzinga · 03/22 11:29
New Strong Sell Stocks for March 18th
NASDAQ · 03/18 13:15
Weekly Report: what happened at TRDA last week (0311-0315)?
Weekly Report · 03/18 11:08
Entrada Therapeutics Price Target Maintained With a $20.00/Share by HC Wainwright & Co.
Dow Jones · 03/18 10:48
HC Wainwright & Co. Reiterates Buy on Entrada Therapeutics, Maintains $20 Price Target
Benzinga · 03/18 10:38
Entrada Therapeutics: Buy Rating on Strong Financials and Promising Clinical Pipeline
TipRanks · 03/18 10:25
Entrada Therapeutics GAAP EPS of -$0.29 beats by $0.81, revenue of $41.85M
Entrada Therapeutics Q4 GAAP EPS of -$0.29 beats by $0.81, revenue of $41.85M. $352 million in cash, cash equivalents and marketable securities as of December 31, 2023. Earnings were better than expected.
Seeking Alpha · 03/14 06:56
More
Webull provides a variety of real-time TRDA stock news. You can receive the latest news about Entrada Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About TRDA
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a class of medicines, which engages intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through its proprietary, highly versatile and modular EEV platform (EEV Platform), the Company is building a robust development portfolio of therapeutic candidates. Its first two drug candidates, ENTR-601-44 and VX-670, are in clinical trials. VX-670 for dystrophy type 1 (DM1) is designed to block the triplet repeats in the messenger RNA (mRNA). ENTR-601-44 is in a Phase I clinical trial. The Company also announced the selection of additional clinical candidates within its Duchenne franchise, ENTR-601-45 and ENTR-601-50.